PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
PHIBRO ANIMAL HEALTH CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026
$39.34+0.52 (+1.34%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
PHIBRO ANIMAL HEALTH CORP revenue by segment
By business segment
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $297.56M | $291.23M | $289.98M | $283.46M | $292.48M | $258.38M | $229.42M | $182.52M | $191.52M | $181.33M | $173.10M | $160.53M | 75.0% | +1.7% |
| Mineral Nutrition | $76.99M | $73.42M | $68.95M | $62.99M | $64.15M | $66.77M | $63.25M | $59.06M | $62.06M | $64.23M | $61.35M | $56.03M | 19.4% | +20.0% |
| Performance Products | $22.20M | $18.90M | $14.99M | $17.45M | $22.07M | $22.67M | $16.59M | $18.85M | $19.59M | $17.66M | $15.49M | $14.79M | 5.6% | +0.6% |
By product or service
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $297.56M | $291.23M | $289.98M | $283.46M | $292.48M | $258.38M | $229.42M | $182.52M | $191.52M | $181.33M | $173.10M | $160.53M | 75.0% | +1.7% |
| MFAs and other | $207.63M | $205.79M | $202.11M | $195.20M | $206.53M | $181.65M | $150.34M | $107.84M | $116.70M | $108.22M | $101.94M | $94.10M | 52.3% | +0.5% |
| Mineral Nutrition | $76.99M | $73.42M | $68.95M | $62.99M | $64.15M | $66.77M | $63.25M | $59.06M | $62.06M | $64.23M | $61.35M | $56.03M | 19.4% | +20.0% |
| Nutritional Specialties | $49.88M | $46.81M | $50.23M | $48.15M | $47.38M | $43.35M | $45.91M | $42.65M | $42.83M | $40.19M | $41.44M | $40.21M | 12.6% | +5.3% |
| Vaccines | $40.05M | $38.63M | $37.64M | $40.11M | $38.57M | $33.38M | $33.17M | $32.03M | $31.99M | $32.92M | $29.73M | $26.22M | 10.1% | +3.8% |
| Performance Products | $22.20M | $18.90M | $14.99M | $17.45M | $22.07M | $22.67M | $16.59M | $18.85M | $19.59M | $17.66M | $15.49M | $14.79M | 5.6% | +0.6% |
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $220.25M | $232.77M | $221.76M | $202.35M | $201.99M | $209.94M | $184.44M | $143.55M | $153.68M | $159.31M | $140.48M | $131.29M | 55.5% | +9.0% |
| Latin America and Canada | $90.22M | $75.62M | $87.60M | $87.23M | $84.07M | $70.75M | $72.67M | $71.15M | $70.17M | $53.65M | $65.18M | $58.70M | 22.7% | +7.3% |
| Europe, Middle East and Africa | $53.75M | $44.47M | $44.78M | $44.94M | $57.61M | $38.91M | $32.59M | $31.13M | $32.41M | $33.18M | $29.52M | $26.88M | 13.5% | -6.7% |
| Asia Pacific | $32.52M | $30.69M | $19.77M | $29.38M | $35.03M | $28.22M | $19.56M | $14.61M | $16.91M | $17.08M | $14.76M | $14.48M | 8.2% | -7.2% |
From the segment and revenue-disaggregation notes of Phibro Animal Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.